Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | USP5 | P45974 | 1/20 | 0.32 |
| ▸ | USP9X | Q93008 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17449172 | 0.89 | MAPT (0.39) | IRAK4ALDH1A1HPGD | |
| SCHEMBL17440632 | 0.80 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL17440633 | 0.80 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL17440495 | 0.79 | ALDH1A1 (0.39) | IRAK4UCHL1USP5USP9XCTSA | |
| SCHEMBL17449448 | 0.78 | IRAK4 (0.35) | IRAK4DUT | |
| SCHEMBL2768666 | 0.75 | MAPT (0.39) | IRAK4ALDH1A1HPGD | |
| SCHEMBL17440955 | 0.72 | CTSA (0.40) | IRAK4UCHL1USP5USP9XCTSA | |
| SCHEMBL21962295 | 0.72 | MEN1 (0.38) | DUTALDH1A1 | |
| SCHEMBL12342046 | 0.72 | MAPT (0.40) | IRAK4ALDH1A1HPGD | |
| SCHEMBL17440703 | 0.72 | IRAK4 (0.35) | IRAK4UCHL1USP5USP9XALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885DUT 4104/4885UCHL1 3840/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885DUT 4104/4885UCHL1 3840/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885DUT 3932/4885UCHL1 3797/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885DUT 3932/4885UCHL1 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.